Systematic Review of the Registered Clinical Trials of Coronavirus Disease 2019 (COVID-19)

Rui-fang Zhu[3#], Yu-lu Gao[2#], Sue-Ho Robert[4], Jin-ping Gao[3], Shi-gui Yang[5], Chang-tai Zhu[1*]

[1] Department of Transfusion Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

[2] Department of Laboratory Medicine, Kunshan Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Kunshan, Jiangsu Province, China

[3] School of Nursing, Shanxi Medical University, 56 Xinjian South Road, Yingze District, Taiyuan, Shanxi Province, China

[4] Infection Service, University Hospital of Coventry and Warwickshire (UHCW) NHS Trust, Clifford Bridge Road, Coventry CV2 2DX, United Kingdom

[5] State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

[*]Correspondence to:

Prof Changtai Zhu, Department of Transfusion Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China zct101@163.com

Conflict of interest: None.

[#] These authors are contributed equally to this work.

Abstract

Background: Since the outbreak of coronavirus disease 2019 (COVID-19), many researchers in China have immediately carried out clinical research scheme of the COVID-19. But, there is still a lack of systematic review of registered clinical trials. Therefore, we conducted a systematic review of the clinical trials of COVID-19 to summarize the characteristics of the COVID-19 registered clinical trials. **Methods:** This study is based on the recommendations of the PRISMA in the Cochrane handbook. The databases from the Chinese Clinical Registration Center and the ClinicalTrials.gov were searched to collect the registered clinical trials of COVID-19. The retrieval inception date is February 9, 2020. Two researchers independently selected the literature based on inclusion and exclusion criteria, extracted data and evaluated the risk of bias. **Results:** A total of 75 registered clinical trials (63 interventional studies and 12 observational studies) of COVID-19 were obtained. A majority of clinical trials were sponsored by Chinese hospitals. Only 11 trials have begun to recruit patients, and none of the registered clinical trials had been completed; 34 trials were early clinical exploratory trials or in a pre-experiment stage, 15 trials belonged to phrase III and 4 trials were phrase IV. The methods of intervention included traditional Chinese medicine involving 26 trials, Western medicine involving 30 trials, and integrated traditional Chinese medicine and Western medicine involving 19 trials. The subjects were mainly non-critical adult patients (≥ 18 years old). The median sample size of the trials was 100 (IQR: 60 - 200), and the median execute time of the trials was 179 d (IQR: 94 - 366 d). The main outcomes were clinical observation and examinations. Overall, both the methodology quality of interventional trials and observational studies were low. **Conclusions:** Disorderly and intensive clinical trials of COVID-19 using traditional Chinese medicine and western medicine are ongoing or will being carried out in China. However, based on the low methodology quality and small sample size and long studies execute time, we will not be able to obtain reliable, high-quality clinical evidence about COVID-19 treatment in the near future. Improving the quality of study design, prioritizing promising drugs, and using different designs and statistical methods are worth advocating and recommending for the clinical trials of COVID-19 in China.

Keywords: systematic review; COVID-19; 2019-nCoV; new coronavirus pneumonia; registered clinical trial; interventional trial; observational study

Coronavirus disease 2019 (COVID-19), being an emerging infectious disease, is a serious threat to human health [1-3]. In December 2019, the initial outbreak of COVID-19 in Wuhan city, Hubei province of China, was suspected to be related to the seafood market, and chrysanthemum head bat was suspected to be the host of the new coronavirus [4-7]. Patients with COVID-19 show manifestations of respiratory tract infection, such as fever, cough, pneumonia, and in severe cases, death [8, 9]. According to a recent survey, the mortality rate of the viral disease is estimated to be about 2% - 4% [8, 10]. By Feb 29, 2020, more than 80,000 people were confirmed to be infected around the world, with most of them belonging to China. At present, there are different number of infected people in different provinces of China, with Hubei Province being the most seriously affected one), and the signs of infection outbreak are obvious. In addition, more than 40 countries around the world have also seen new cases of COVID-19 [11-15]. Therefore, COVID-19 is a great challenge to human health [10, 16].

Little is known about COVID-19 as it is a new infectious disease; therefore, presently there is no specific treatment available for COVID-19. To date, no clinical intervention trial has been completed and reported. Due to the urgent need for treatment prevention and control of the disease, it is necessary to develop effective intervention methods for COVID-19 to facilitate disease control. Since the outbreak of the COVID-19, many researchers in China have carried out clinical research trials, aiming to develop strategies for the treatment, prevention and diagnosis of COVID-19. However, up to now, there is still a lack of systematic appraisal of the registered clinical trials COVID-19. Therefore, we conducted a systematic review of the clinical trials of COVID-19 to analyze the characteristics and existing problems of the registered clinical trials.

Materials and methods

Inclusion criteria

This review was performed according to the Cochrane Handbook for Systematic Reviews of Interventions [17] and presented based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines [18].

The inclusion criteria of this study were: patients with COVID-19; clinical trials with protocol; trials involving the diagnosis, prevention and treatment of COVID-19; trials having clear and specific end-point outcomes; and trials with any type of study design.

Exclusion criteria

The exclusion criteria of this study were: animal trials; theoretical research; and unregistered clinical trials.

Retrieval strategies

The literature retrieval was independently completed by two researchers. The databases from the Chinese clinical trial registration center and the ClinicalTrials.gov were used for data search. No language limitations were specified for the search, and the search deadline was February 9, 2020. The following key words were applied: new coronavirus, COVID-19, 2019-nCoV pneumonia, novel coronavirus pneumonia, 2019-nCoV infection, new coronavirus infection, new coronavirus, etc.

Data extraction

The contents that were extracted mainly included registration number, project name, research leader, research type, study design, sponsor, implementation unit, start time, completion period, research site, research institute, stage, research object, inclusion standard, exclusion standard, sample size, setting, location, recruitment period, intervention group measures, control group measures, random methods, blind methods, distribution concealment and measurement indicators. Literature evaluation was independently conducted by two researchers.

Methodology quality assessment

The quality evaluation and data extraction of each literature fulfilling the inclusion criteria was conducted independently and a cross- check was carried out. Arguments or disagreement of opinions were resolved by a discussion between the two researchers. The randomized controlled trial was based on Cochrane risk of bias items, which includes: randomization sequence generation, allocation concealment, blinding of

participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias [19]. The observational study was based on the quality evaluation by Newcastle-Ottawa scale (NOS) [20].

Summary and synthesis

This review presents a narrative synthesis. This study mainly analyzes and summarizes the types of studies, intervention, host organization and address, sample size, research stage, research status, expected completion time, inclusion and exclusion criteria, outcome measurement and observation time, and methodology quality and describes the results with statistics and characteristics. Non-parametric data are represented by median and 95% CI and the statistical analysis used MedCalc statistical software (version 15.2.2, MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2015). The bias plot was performed by Review Manager (RevMan) [Computer program] (version 5.2, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012).

Results

Trial search results

Up to February 9, 2020, we retrieved a total of 75 clinical trials of COVID-19 from the Chinese clinical registration center, and 18 clinical trials of COVID-19 from the ClinicalTrails.gov, and a total of 75 clinical trials of COVID-19 were obtained (Table 1 and Table 2). The retrieval process is shown in Figure 1.

General characteristics of the clinical trials

The trials were sponsored by Chinese organizations, except for two from France (NCT04262921, NCT04259892). The following organizations sponsored more than three trials: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; The First Affiliated Hospital, College of Medicine, Zhejiang University; Xinhua Affiliated Hospital, Hubei University of Chinese Medicine; Zhejiang Chinese Medical University; Shanghai Public Health Clinical Center; and Hospital of Chengdu University of Traditional Chinese Medicine (Figure 2). The study sponsors belonged to different regions such as Hubei, Beijing, Zhejiang, Guangdong, Sichuan, Shanghai, etc. From the

perspective of research type, most of them were interventional studies mainly aiming at drug therapy, and 12 were observation studies.

Most of the trials have passed the ethical review, whereas some are still in the preparation stage and only 11 trials have just started to recruit patients, however, none of the registered clinical trials have been completed. The first trial registered on January 23, 2020 was a randomized controlled trial of "A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus pneumonia (COVID-19)", which was sponsored by the Wuhan Jinyintan Hospital.

In terms of trial stages, 34 trials were exploratory or in the preliminary experiment stage (phrase 0 clinical trial), 15 studies were in the extended validation stage with indications of drugs in the market (phrase IV), only 4 trials in phrase III ("NCT04252664, Mild/Moderate 2019-nCoV Remdesivir RCT" and NCT04257656, Severe 2019-nCoV Remdesivir RCT" by Cao B *et al*; "NCT04252274, Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV and NCT04261517, Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV) by Lu H *et al*; each individual study included hundreds of samples". However, other studies belonged to the unspecified items.

The median sample size was 100 (IQR: 60 − 200), and the median execute time of the studies was 179 d (IQR: 94 − 366 d). General characteristics of the clinical trials were summarized in Table 3 and Table 4.

Characteristics of inclusion criteria

The common characteristics of inclusion criteria included: signing informed consent; age over 18 years; laboratory test (RT-PCR) confirmed infection of COVID-19 (diagnostic criteria for pneumonia diagnosis in line with "Protocol of Prevention and Control of Novel Coronavirus Pneumonia"); chest imaging confirmed lung involvement; participants were willing to be assigned to any designated treatment group randomly; and participants agreed not to participate in another study of the investigator until completion of the present study Most of the studies were limited to light subjects (ordinary subjects), and few of the studies included severe patients.

Characteristics of exclusion criteria

The common characteristics of the exclusion criteria were: critical patients with COVID-19; pregnant and lactating women; allergic patients; patients with tumors or serious heart, brain, kidney, and hemoglobin disease and other diseases; patients with mental disorders, drug abuse or dependence history; subjects who failed to get informed consent; and researchers' opinion that the subject is not suitable for the study.

Intervention and comparison

The main intervention methods of registered clinical trials included treatment with traditional Chinese medicine, western medicine, and integrated traditional Chinese and western medicine. The outcomes of treatment observation mainly included clinical rehabilitation time, incidence of using mechanical ventilation, incidence in ICU, mortality, all kinds of complications and virological detection indicators, etc. The medication methods mainly included oral, injection, atomization inhalation, etc.; the medication time was generally more than one week. The time period of outcome was more than 2−4 weeks. The controls were treated either with placebo or routine treatment.

Among the registered clinical trials, 30 were Western medicine-based treatments, and the methods of intervention mainly included: i) antiviral drugs, such asrhetcivir, Abidol, fabiravir, chloroquine phosphate, asc09/ritonavir compound tablets, lopinavir/ritonavir (Coriolus), hydroxychloroquine, chloroquine, baloxavir, darunavir/Corbis, etutabine/propofol tenofovir, etc.; ii) antiviral drugsin combination with biological agents, such aslucotinib combined with mesenchymal stem cell therapy, recombinant cytokine gene derived protein injection combined with Abidol or lopinavir/ritonavir, recombinant virus macrophage inflammatory protein for aerosol inhalation injection or lopinavir/ritonavir tablets combined with thymosin A1, and lopinavir/ritonavir combined with interferon-α2b; iii) biological agents (products), such as uterine blood stem cells, interferon, cord blood mononuclear cells, cord mesenchymal stem cell conditioned medium, recombinant cytokine gene-derived protein, immunoglobulin, etc.; and iv)steroid therapy, for example, glucocorticoids (intervention in critical patients).

There were 26 registered clinical trials with traditional Chinese medicine treatment. Traditional Chinese medicine treatment drugs were mainly various kinds of Chinese herbal medicines (decoction, capsule, granule, etc.), including Feiyanyihao, Qingfeijiedutang, Xinguanyihao, Lianhuaqingwen capsule, etc. The main ingredients of these drugs included antiviral and immunomodulatory Chinese herbal formulas. In addition, traditional Chinese medicine treatment also involved certain traditional Chinese medicine injection, such as Xuebijin Injection, Shuanghuanglian injection and Tanreqing injection.

There were 19 registered clinical trials using a combination treatment of Chinese and western medicine, and the intervention included the combination of the above mentioned Chinese herbs and western antiviral drugs.

Outcomes and timing of measurement

The outcomes mainly included: clinical symptoms, mortality, chest CT, viral nucleic acid detection, body temperature, clinical improvement, critically ill patients (%); lung function; the time to 2019-nCoV RNA negativity in patients, time for lung recovery, mechanical ventilation time; length of stay in hospital, time for body temperature recovery, inflammatory cytokines, SOFA score, St Georges respiratory questionnaire, SGRQ, modified Barthel Index, MBI, and incidence of adverse events. Additionally, some other laboratory tests for novel coronavirus were also selected, including routine blood test, routine urine test, C-reactive protein, procalcitonin, erythrocyte sedimentation rate, muscle enzyme, troponin, myoglobin, D dimer, blood gas analysis, coagulation routine, new coronavirus nucleic acid test, T cell subgroup analysis, hospitalization period etc.

The follow-up period of the outcome measure was mostly 2−4 weeks, but some studies did not set forth a plan.

Methodology quality

According to the Cochrane bias risk assessment results (Figure 3), the quality assessment of the interventional study methodology is generally low. Most trials reported randomization, while the other trials had high risk of biases in randomization (17 trials did not mention randomization and 6 trials were judged as non-randomized trials）; Few trials conducted distribution concealment; only nine trials implemented blinding of

participants, personnel and outcome assessment; None of the 63 trials clarified drop-out and follow-up bias. However, other bias risks, such as the risk of conflict of interest among drug manufacturers, are unclear.

The NOS scores of the observational trials are from 4 to 6 (Table 3). Most of the observational trials have high risk of biases in assessment outcome, follow-up of outcome and adequacy of follow up of cohorts (Figure 4). Therefore, the overall quality of registered observational trials is low.

Discussion

COVID-19, being a new and poorly understood infectious disease, has no recognized effective treatment strategy. Coronavirus outbreak has caused great harm to China and seriously threatened people's health [21-23]. To deal with the disease, many intensive clinical trials have been carried out. Database search results indicated that current studies were mainly from China, involving the treatment with traditional Chinese medicine, Western medicine, and the combination of traditional Chinese and Western medicine and the primary sponsors were mainly the hospitals of China. However, the median sample size of the trials was 100 (IQR: 60 – 200) and most trials had a small sample size. Hence, the future evidence level of these studies is low.

According to the summary results, only 11 trials have begun to recruit patients, and none of the registered clinical trials had been completed. Of them, 34 trials were early clinical exploratory trials or in a pre-experiment stage (phrase 0). Fifteen trials belonged to phrase IV and some drugs that have been licensed for other diseases such as chloroquine phosphate, abidol, fabiravir, asc09/ritonavir compound tablets, lopinavir/ritonavir, hydroxychloroquine, chloroquine, etc. were used in registered clinical trials of COVID-19. Four studies were phase III clinical trials with remdesivir, darunavir and cobicistat, and hydroxychloroquine.

The main methods of intervention included traditional Chinese medicine involving 26 trials, Western medicine involving 30 trials, and integrated traditional Chinese medicine and Western medicine involving 19 trials.

At present, conventional treatment strategies for COVID-19 mainly involve use of antivirals, improving patients' immunity, intervening autoimmune damage (against immune storm caused by cytokines), and symptomatic treatment. Western drugs have been shown to be superior to traditional Chinese medicine in terms of *in vitro* antiviral effect. However, as Chinese herbs have both antiviral and immunomodulatory effects based on low quality clinical evidence, they have the potential value in the prevention and treatment of COVID-19.

There were 26 registered clinical trials with traditional Chinese medicine treatment and 19 registered clinical trials using a combination treatment of Chinese and western medicine, suggesting that traditional Chinese medicine is a popular candidate for therapeutic drugs against COVID-19. At present, the combination of Chinese and western medicines (Qingfeipaidutang and chloroquine phosphate, abidol, lopinavir/ritonavir) is considered a better treatment strategy by experts, and has been listed in the "Protocol of Prevention and Control of Novel Coronavirus Pneumonia"; however, there is still a lack of high-quality evidence, and clinical verification is required.

Existing preliminary evidences suggest that the antiviral drug remdesivir (phase III clinical trials for light, moderate, and severe patients, expected to end on April 27, 2020) has a promising application prospect. The reasons are as follows: i) *in vitro* and *in vivo* cell test results indicated that even very low concentration of the drug has an antiviral effect [24, 25]; ii) animal trials have proved the drug safe for use [26]; and iii) "clinical tests indicate that the drug is effective against Ebola virus [27, 28]; iv) clinical case report is effective [29]. In addition, some of the validation drugs, such as chloroquine phosphate, Abidol, darunavir, and lopinavir/ritonavir (Coriolus Versicolor), have been proven safe and have shown strong antiviral potential *in vitro* [25]. Thus, these Western antiviral drugs have an application potential which needs to be verified in clinical practice.

In this review, we found that many trials used biological agents for immunotherapy of the disease. In light of the experience and lessons of severe acute respiratory syndrome (SARS) [30, 31], steroid therapy has been used cautiously in the treatment of COVID-19; therefore, we found only a few studies on steroid therapy.

From the perspective of inclusion and exclusion criteria, some people were excluded, such as children and adolescents, pregnant women, and patients with serious liver and kidney damage. Therefore, there is a lack of clinical evidence in this portion of the population.

The outcomes of clinical trial observation included clinical observation outcomes, physical examination and laboratory test results, however, some outcomes were subjective leading to measurement bias.

Based on Cochrane risk of bias items and NOS, we evaluated the quality of interventional trials and observational trials, respectively. The evaluation results showed that the overall quality of the registered clinical trials was low, indicating that most of the registered clinical studies had a greater risk of bias, and the level of evidence is relatively low in the future, which belittles the practice significance of the research. We believed that it is difficult to obtain reliable and high-quality evidence in near future. The main reasons for the low quality of the registered clinical trial protocols could be: i) insufficient clinical research ability of the researchers; and ii) researchers' lack of experience in dealing with sudden health events.

We believed that it is necessary to improve the quality of research and to the registered clinical research programmes in strict accordance with the guidelines for clinical trials [32-35]. In addition, current clinical trials by different hospitals conducted spontaneously are not effectively organized and coordinated, so more scattered and disorderly. Some drugs that have not been tested in vitro or whose safety is of great concern are also being tested in clinical trials, which not only increase the risk of clinical trials, but also waste research resources. Hence, the administration of scientific research should strengthen their management and coordination and few promising drugs should be prioritized for clinical trials.

From these registered clinical studies, we found a serious limitation: most of the registered clinical research did not consider the "timeliness", and still followed the conservative traditional study design paradigm. The median execute time (days) of the studies was 179 d (IQR: 94 – 366 d), which is highly unfavorable in the current critical situation. We believe that, in the current situation, the "timeliness" factor should be given

importance in the design of clinical trials, so that the research does not lose its social significance. Therefore, in this critical situation, it is better to refer to the "sequential design" for clinical trials; "sequential design" not only requires small sample size, but also significantly shortens the research during, therefore, it is very conducive to the screening and discovery of drugs with significant efficacy [36, 37]. In addition, a very difficult problem is the treatment of severe and critical patients with COVID-19. For these patients, we suggested that: based on the "compassionate use drug" principle, with safe and obvious antiviral potential drugs, to conduct a staged small batch and single-arm clinical trials is feasible. We believed that "compassionate use drug" can not only meet the special needs of patients but also perform clinical effectiveness observation, research and analysis, so as to enhance the efficiency of research and benefit the patients [38-42]. Also, given a large number of clinical cases have accumulated information, and using available existing data for statistics and analysis with the help of new statistical methods such as clinical data-mining [43-45] and real-world study [46-48], etc., can help in quickly obtaining some very valuable information and save research time.

In brief, under the condition that there are a large number of cases to be selected at present, it is of great value for the treatment and prevention of COVID-19 to try to complete various clinical trial designs and data analysis scientifically and efficiently with a variety of clinical research designs and statistical analysis methods, and researchers should try in future.

Conclusions

Disorderly and intensive clinical trials of COVID-19 using traditional Chinese medicine and Western medicine are ongoing or will be carried out in China. However, based on the poor quality and small sample size and long study execute period, we will not be able to obtain reliable, high-quality clinical evidence about COVID-19 treatment for quite a long time in the future. In order to effectively deal with the current sudden health emergencies, the National Administration of scientific research should strengthen their management and coordination to improve the study quality based on the guidelines for clinical trials. Also, it is important to ensure that some promising projects are prioritized.

In addition, we suggest that using a variety of study designs and statistical methods to scientifically and efficiently conduct the clinical trials, which has an extremely important value for the control of COVID-19.

Declaration of interests

The authors declare that there is no conflict of interest.

References:

1. The LID: **Challenges of coronavirus disease 2019**. *LANCET INFECT DIS* 2020.10.1016/S1473-3099(20)30072-4.
2. Burki T: **Outbreak of coronavirus disease 2019**. *LANCET INFECT DIS* 2020.10.1016/S1473-3099(20)30076-1.
3. **The Novel Coronavirus Outbreak: What We Know and What We Don't**. *CELL* 2020.10.1016/j.cell.2020.02.027.
4. She J, Jiang J, Ye L, Hu L, Bai C, Song Y: **2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies**. *Clin Transl Med* 2020, **9**(1):19.10.1186/s40169-020-00271-z.
5. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL *et al*: **A pneumonia outbreak associated with a new coronavirus of probable bat origin**. *NATURE* 2020.10.1038/s41586-020-2012-7.
6. Ribeiro J, Bingre P, Strubbe D, Reino L: **Coronavirus: why a permanent ban on wildlife trade might not work in China**. *NATURE* 2020, **578**(7794):217.10.1038/d41586-020-00377-x.
7. York A: **Novel coronavirus takes flight from bats?** *NAT REV MICROBIOL* 2020.10.1038/s41579-020-0336-9.
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y *et al*: **Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China**. *JAMA* 2020.10.1001/jama.2020.1585.
9. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN *et al*: **Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series**. *BMJ* 2020, **368**:m606.10.1136/bmj.m606.
10. Mahase E: **Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate**. *BMJ* 2020, **368**:m641.10.1136/bmj.m641.
11. Silverstein WK, Stroud L, Cleghorn GE, Leis JA: **First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia**. *LANCET* 2020.10.1016/S0140-6736(20)30370-6.
12. Pongpirul WA, Pongpirul K, Ratnarathon AC, Prasithsirikul W: **Journey of a Thai Taxi Driver and Novel Coronavirus**. *N Engl J Med* 2020.10.1056/NEJMc2001621.
13. Malik MR, Mafi AR, Mahjour J, Opoka M, Elhakim M, Muntasir MO: **Novel coronavirus infection in the eastern mediterranean region: time to act**. *East Mediterr Health J* 2013, **19 Suppl 1**:S31-S38
14. Bastola A, Sah R, Rodriguez-Morales AJ, Lal BK, Jha R, Ojha HC, Shrestha B, Chu D, Poon

L, Costello A *et al*: **The first 2019 novel coronavirus case in Nepal**. *LANCET INFECT DIS* 2020.10.1016/S1473-3099(20)30067-0.

15. Gostin LO, Hodge JJ: **US Emergency Legal Responses to Novel Coronavirus: Balancing Public Health and Civil Liberties**. *JAMA* 2020.10.1001/jama.2020.2025.

16. Mallapaty S: **Scientists fear coronavirus spread in countries least able to contain it**. *NATURE* 2020, **578**(7795):348.10.1038/d41586-020-00405-w.

17. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J: **Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions**. *Cochrane Database Syst Rev* 2019, **10**:D142.10.1002/14651858.ED000142.

18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: **The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration**. *BMJ* 2009, **339**:b2700.10.1136/bmj.b2700.

19. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J: **Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions**. *Cochrane Database Syst Rev* 2019, **10**:D142.10.1002/14651858.ED000142.

20. Stang A: **Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses**. *EUR J EPIDEMIOL* 2010, **25**(9):603-605.10.1007/s10654-010-9491-z.

21. **Communication, collaboration and cooperation can stop the 2019 coronavirus**. *NAT MED* 2020, **26**(2):151.10.1038/s41591-020-0775-x.

22. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y *et al*: **Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study**. *LANCET* 2020, **395**(10223):507-513.10.1016/S0140-6736(20)30211-7.

23. Wu JT, Leung K, Leung GM: **Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study**. *LANCET* 2020.10.1016/S0140-6736(20)30260-9.

24. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H: **Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection**. *Proc Natl Acad Sci U S A* 2020.10.1073/pnas.1922083117.

25. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G: **Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro**. *CELL RES* 2020.10.1038/s41422-020-0282-0.

26. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO *et al*: **Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV**. *NAT COMMUN* 2020, **11**(1):222.10.1038/s41467-019-13940-6.

27. Brown AJ, Won JJ, Graham RL, Dinnon KR, Sims AC, Feng JY, Cihlar T, Denison MR, Baric RS, Sheahan TP: **Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase**. *Antiviral Res*

2019, **169**:104541.10.1016/j.antiviral.2019.104541.

28. Tchesnokov EP, Feng JY, Porter DP, Gotte M: **Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir**. *Viruses* 2019, **11**(4).10.3390/v11040326.

29. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A *et al*: **First Case of 2019 Novel Coronavirus in the United States**. *N Engl J Med* 2020.10.1056/NEJMoa2001191.

30. Zhao FC, Guo KJ, Li ZR: **Osteonecrosis of the femoral head in SARS patients: seven years later**. *Eur J Orthop Surg Traumatol* 2013, **23**(6):671-677.10.1007/s00590-012-1054-4.

31. Zhao R, Wang H, Wang X, Feng F: **Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis**. *Osteoporos Int* 2017, **28**(3):1027-1034.10.1007/s00198-016-3824-z.

32. Li J, Hu JY, Zhai JB, Niu JQ, Kwong J, Ge L, Li B, Wang Q, Wang XQ, Wei D *et al*: **CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM) : Recommendations, explanation and elaboration**. *COMPLEMENT THER MED* 2019, **46**:180-188.10.1016/j.ctim.2019.08.014.

33. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR *et al*: **SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials**. *BMJ* 2013, **346**:e7586.10.1136/bmj.e7586.

34. Schulz KF, Altman DG, Moher D: **CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials**. *BMJ* 2010, **340**:c332.10.1136/bmj.c332.

35. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP: **Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies**. *BMJ* 2007, **335**(7624):806-808.10.1136/bmj.39335.541782.AD.

36. Zhu H, Yu Q, Mercante DE: **A Bayesian sequential design with binary outcome**. *PHARM STAT* 2017, **16**(3):192-200.10.1002/pst.1805.

37. Cui L, Zhang L, Yang B: **Optimal adaptive group sequential design with flexible timing of sample size determination**. *CONTEMP CLIN TRIALS* 2017, **63**:8-12.10.1016/j.cct.2017.04.005.

38. Puthumana J, Miller JE, Kim J, Ross JS: **Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs**. *JAMA Netw Open* 2018, **1**(2):e180283.10.1001/jamanetworkopen.2018.0283.

39. Edgeworth JD, Merante D, Patel S, Young C, Jones P, Vithlani S, Wyncoll D, Roberts P, Jones A, Den Nagata T *et al*: **Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa**. *CLIN INFECT DIS* 2019, **68**(11):1932-1934.10.1093/cid/ciy963.

40. Van Norman GA: **Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try"**. *JACC Basic Transl Sci* 2018, **3**(2):280-293.10.1016/j.jacbts.2017.11.007.

41. Lardizabal AA, Khan AN, Bamrah MS, Goswami ND: **Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017**. *MMWR Morb Mortal Wkly Rep* 2018, **67**(35):996-997.10.15585/mmwr.mm6735a6.

42. Holbein M, Weatherwax KJ, Gravelin M, Hutchinson R, Mashour GA: **Right now, in the right way: U. S. Food and Drug Administration's expanded access program and patient rights**.

J Clin Transl Sci 2018, **2**(3):115-117.10.1017/cts.2018.318.

43. Zeng QT, Fodeh S: **Clinical data mining**. *COMPUT BIOL MED* 2015, **62**:293.10.1016/j.compbiomed.2015.05.014.

44. Ghaibeh AA, Kasem A, Ng XJ, Nair H, Hirose J, Thiruchelvam V: **Gaining Insights on Nasopharyngeal Carcinoma Treatment Outcome Using Clinical Data Mining Techniques**. *Stud Health Technol Inform* 2018, **247**:386-390

45. Larsson K, Fredriksson RK, Sjogren FK: **Health social workers' assessments as part of a specialized pain rehabilitation: a clinical data-mining study**. *SOC WORK HEALTH CARE* 2019, **58**(10):936-951.10.1080/00981389.2019.1679322.

46. Galffy G, Szilasi M, Tamasi L: **Effectiveness and Patient Satisfaction with Budesonide/Formoterol Easyhaler((R)) Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes**. *Pulm Ther* 2019, **5**(2):165-177.10.1007/s41030-019-0097-7.

47. Gustafson WL, Saunders J, Vazquez SR, Jones AE, Witt DM: **Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation**. *Pharm Pract (Granada)* 2019, **17**(4):1709

48. Lv XY, Ding HG, Zheng JF, Fan CL, Li L: **Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study**. *World J Gastroenterol* 2020, **26**(2):199-218.10.3748/wjg.v26.i2.199.

Table 1 Summary of intervention registered clinical trials.

No	Register number	Study leader (year)	Primary sponsor	Study name
1	ChiCTR2000029638	Liu L 2020	West China Hospital, Sichuan University	Multicenter randomized controlled trial for novel recombinant high-efficiency compound interferon in the treatment of novel coronavirus pneumonia (COVID-19)
2	ChiCTR2000029387	Chen Y 2020a	Chongqing Public Health Medical Center	Comparison of efficacy and safety of three antiviral regimens in patients with mild to moderate novel coronavirus pneumonia (COVID-19): a randomized controlled trial
3	ChiCTR2000029386	Chen Y 2020b	Chongqing Public Health Medical Center	Adjunctive corticosteroid therapy for Patients with Severe Novel coronavirus pneumonia (COVID-19): a randomized controlled trial
4	ChiCTR2000029435	Wei L 2020	Wuhan First Hospital	Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population
5	ChiCTR2000029308	Huang C 2020	Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)	A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus pneumonia (COVID-19)
6	ChiCTR2000029400	Hung L 2020	China Academy of Chinese Medical Sciences	Clinical controlled trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)

7	ChiCTR2000029418	Liang T 2020	Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine	Chinese herbal medicine for severe novel coronavirus pneumonia (COVID-19): a randomized controlled trial
8	NCT04244591	Du B 2020	Peking Union Medical College Hospital	Glucocorticoid therapy for novel coronavirus critically ill patients with severe acute respiratory failure
9	NCT04251871	Wang R 2020	Beijing 302 Hospital	Treatment and prevention of traditional Chinese medicines (TCMs) on 2019-nCoV infection
10	ChiCTR2000029436	Li J 2020	The First Hospital of He'nan University of Chinese Medicine	A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)
11	ChiCTR2000029432	Yang Z 2020	The First Afflicated Hospital of Guangzhou University of Chinese Medicine	A real world study for the efficacy and Safety of large dose tanreqing injection in the treatment of patients with novel coronavirus pneumonia (COVID-19)
12	ChiCTR2000029431	Zhao D 2020	Affiliated Zhongshan Hospital of Dalian University	Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)
13	ChiCTR2000029381	Zhong N 2020	The First Affiliated Hospital of Guangzhou Medical University	A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)
14	ChiCTR2000029487	Su W 2020	Wuhan Hospital of Integrated Traditional Chinese and	Clinical study for Gu-Biao Jie-Du-Ling in preventing of 2019-nCoV pneumonia (Novel coronavirus pneumonia, NCP)

			Western Medicine	in children
15	ChiCTR2000029479	Tang J 2020	Hospital of Chengdu University of Traditional Chinese Medicine	Research for traditional Chinese medicine technology prevention and control of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) in the community population
16	ChiCTR2000029468	Jiang H 2020	Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital	A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
17	ChiCTR2000029461	Xia W 2020	Xinhua affiliated hospital, Hubei University of Chinese Medicine	A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP)
18	ChiCTR2000029460	Zheng C 2020	Xinhua affiliated hospital, Hubei University of Chinese Medicine	The effect of shadowboxing for pulmonary function and quality of life in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) in rehabilitation period
19	ChiCTR2000029459	Xia W 2020	Xinhua affiliated hospital, Hubei University of Chinese Medicine	The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) in rehabilitation period
20	ChiCTR2000029439	Wang Y 2020	Beijing hospital of Traditional Chinese medicine	Combination of traditional chinesemedicne and western medicine in the treatment of common type 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)

21	ChiCTR2000029438	Liu Q 2020	Hubei integrated traditional Chinese and Western Medicine Hospital	A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
22	NCT04252274	Lu 2020a	Shanghai Public Health Clinical Center	Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV
23	NCT04261517	Lu 2020b	Shanghai Public Health Clinical Center	Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV)
24	ChiCTR2000029544	Qiu Y 2020a	The First Affiliated Hospital, Zhejiang University School of Medicine	A randomized controlled trial for the efficacy and safety of BaloxavirMarboxil, Favipiravir tablets in 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) patients who are still positive on virus detection under the current antiviral therapy
25	ChiCTR2000029542	Jiang S 2020	Sun Yat-sen Memorial Hospital, Sun Yat-sen University	Study for the efficacy of chloroquine in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
26	ChiCTR2000029541	Wang H 2020	Zhongnan Hospital of Wuhan University	A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
27	ChiCTR2000029539	Zhao J 2020	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)

28	ChiCTR2000029518	Wen C 2020a	Zhejiang Chinese Medical University	Chinese medicine prevention and treatment program for 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a perspective, double-blind, placebo, randomised controlled trial
29	ChiCTR2000029517	Wen C 2020b	Zhejiang Chinese Medical University	Chinese medicine prevention and treatment program for suspected 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a perspective, double-blind, placebo, randomised controlled trial
30	ChiCTR2000029496	Gong G 2020	The Second Xiangya Hospital of Central South University	A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection in eliminating novel coronavirus in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
31	ChiCTR2000029495	Huang M 2020	Xinhua affiliated hospital, Hubei University of Chinese Medicine	Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in Convalescent Period
32	ChiCTR2000029493	Zhang J 2020	Xinhua affiliated hospital, Hubei University of Chinese Medicine	Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in Convalescent Period: a Randomized Controlled Trial
33	ChiCTR2000029580	Zhou J 2020	Tongji Hospital, Tongji Medical College, Huazhong University of	A prospective, single-blind, randomized controlled trial for Ruxolitinib combined with mesenchymal stem cell infusion in the treatment of

			Science and Technology	patients with severe 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
34	ChiCTR2000029589	Liu Q 2020b	Beijing Hospital of Traditional Chinese Medicine	An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
35	ChiCTR2000029600	Liu Y 2020	The Third People's Hospital of Shenzhen	Clinical study for safety and efficacy of Favipiravir in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
36	ChiCTR2000029601	Tong X 2020a	Hubei Provincial Hospital of TCM	Community based prevention and control for Chinese medicine in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) in the isolate suspected and confirmed population
37	ChiCTR2000029602	Tong X 2020b	Hubei Provincial Hospital of TCM	Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population
38	ChiCTR2000029603	Qiu Y 2020a	The First Affiliated Hospital, Zhejiang University School of Medicine	A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP)
39	ChiCTR2000029605	Liu C 2020	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)

40	ChiCTR2000029578	Wen C 2020	Zhejiang Chinese Medical University	Chinese medicine prevention and treatment program for 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a perspective, sing-arm trial
41	ChiCTR2000029573	Li L 2020	Jiehua biotechnology (Qingdao) co. LTD	A multicenter, randomized, open-label, positive-controlled trial for the efficacy and safety of recombinant cytokine gene-derived protein injection combined with abidole, lopinavir/litonavir in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) patients
42	ChiCTR2000029572	Pei B 2020a	Xiangyang First People's Hospital	Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled clinical trial
43	ChiCTR2000029569	Pei B 2020b	Xiangyang First People's Hospital	Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled trial
44	ChiCTR2000029559	Zhang Z2020	Renmin Hospital of Wuhan University	Therapeutic effect of hydroxychloroquine on 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
45	ChiCTR2000029558	Xie C 2020a	Hospital of Chengdu University of Traditional Chinese Medicine	Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in Sichuan Province

46	ChiCTR2000029550	Xie C 2020b	Hospital of Chengdu University of Traditional Chinese Medicine	Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP)
47	ChiCTR2000029549	Xie C 2020c	Hospital of Chengdu University of Traditional Chinese Medicine	Recommendations of Integrated Traditional Chinese and Western Medicine for 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP)
48	ChiCTR2000029548	Qiu Y 2020b	The First Affiliated Hospital, Zhejiang University School of Medicine	Randomized, open-label, controlled trial for evaluating of the efficacy and safety of BaloxavirMarboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) patients
49	NCT04260594	QU 2020	Ruijin Hospital	Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
50	NCT04261907	QIU 2020	First Affiliated Hospital of Zhejiang University	Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus pneumonia
51	NCT04257656	Cao B 2020a	Capital Medical University	Severe 2019-nCoV Remdesivir RCT
52	ChiCTR2000029636	Hu B 2020	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Efficacy and safety of aerosol inhalation of vMIP in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a single arm clinical trial

53	ChiCTR2000029626	Fang X 2020	The First Affiliated Hospital, Zhejiang University School of Medicine	Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in Peripheral Blood of 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) Patients
54	ChiCTR2000029621	Qu J 2020	Ruijin Hospital, Shanghai Jiao Tong University School of Medicine	Clinical study of arbidol hydrochloride tablets in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
55	ChiCTR2000029609	Shan H 2020	The Fifth Affiliated Hospital of Sun Yat-Sen University	A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
56	ChiCTR2000029606	Li L 2020b	The First Affiliated Hospital, College of Medicine, Zhejiang University	Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)
57	ChiCTR2000029625	Cai H 2020	The First Affiliated Hospital, Zhejiang University School of Medicine	Construction of Early Warning and Prediction System for Patients with Severe / Critical 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP)
58	NCT04263402	Han M 2020a	Tongji Hospital	The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
59	NCT04254874	Han M 2020 b	Tongji Hospital	A Prospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
60	NCT04261270	Han M 2020 c	Tongji Hospital	A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia

61	NCT04252664	Cao B 2020 b	Capital Medical University	Mild/Moderate 2019-nCoV Remdesivir RCT
62	NCT04261426	Li 2020	Peking Union Medical College Hospital	The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
63	NCT04255017	Han M 2020d	Tongji Hospital	A Prospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

Table 2 Summary of observational registered clinical trials.

No	Register number	Study leader (year)	Primary sponsor	Study name
1	ChiCTR2000029637	Zhang Z 2020a	Guangdong Provincial Hospital of Chinese Medicine	An observational study for Xin-Guan-1 formula in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
2	ChiCTR2000029430	Zhang Z 2020b	Hubei Integrated Hospital of Traditional Chinese and Western Medicine	Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19)
3	ChiCTR2000029462	Li J 2020	The First Affiliated Hospital of He'nan University of Chinese Medicine	Study for clinical characteristics and distribution of TCM syndrome of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
4	ChiCTR2000029437	Xia W 2020	Hubei Provincial Integrated Hospital of traditional Chinese and Western Medicine	A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)
5	ChiCTR2000029592	Zheng X 2020	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Study for Arbidol Hydrochloride in the Prophylaxis of Novel Coronavirus pneumonia in High-risk Population with History of Exposed to 2019-nCoV pneumonia
6	ChiCTR2000029624	Lu H 2020	Shanghai Public Health Clinical Center	A real world study for traditional Chinese Medicine in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)
7	NCT04262921	Yazdan 2020	Institut National de la Santé Et de la Recherche Médicale, France	Clinical Characterization Protocol for Severe Emerging Infections
8	NCT04256395	Dong 2020	Beijing Tsinghua Chang Gung Hospital	Efficacy of a self-test and self-alert mobile applet in detecting susceptible infection of 2019-nCoV

9	NCT04245631	Xie 2020	Beijing Ditan Hospital	Development of a simple, fast and portable recombinase aided amplification Assay for 2019-nCoV
10	NCT04255940	HAO 2020	Qilu Hospital of Shandong University	2019-nCoV outbreak and cardiovascular diseases
11	NCT04259892	Duval 2020	Institut National de la Santé Et de la Recherche Médicale, France	Viral excretion in contact subjects at high/moderate Risk of coronavirus 2019-nCoV infection
12	ChiCTR2000029579	Zhou J 2020	Tongji Hospital, Huazhong University of Science and Technology	Cytokines profiling and their clinical significance analysis of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) patients

Table 3 Characteristics of the included interventional trials and participants

No	Register number	Study phrase	Start time	End time	Time consuming (days)	Sample	Intervention	Control
1	ChiCTR 2000029638	0	2020-02-03	2020-08-01	179	100	Nebulization of recombinant super-compound interferon (rSIFN-co)	Nebulization of interferon α
2	ChiCTR 2000029387	N/A	2020-01-25	2021-01-25	367	108	Group A: Ribavirin + Interferon alpha-1b Group B: lopinavir / ritonavir + interferon alpha-1b Group C: Ribavirin + LPV/r+Interferon alpha-1b	
3	ChiCTR 2000029386	N/A	2020-01-29	2021-01-29	367	48	Methylprednisolone, intravenous injection	Without any glucocorticoid therapy
4	ChiCTR 2000029435	0	2020-02-01	2020-03-31	60	40	TCM intervention	Placebo
5	ChiCTR 2000029308	N/A	2020-01-10	2021-01-10	367	160	Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and 50 mg of ritonavir)	Conventional standardized treatment
6	ChiCTR 2000029400	0	2020-01-29	2020-12-31	338	60	Group A: traditional Chinese medicine treatment Group B: Lopinavir/Ritonavir Group C: traditional Chinese medicine treatment + Lopinavir/Ritonavir	
7	ChiCTR 2000029418	0	2020-02-03	2020-08-31	211	42	Combined Treatment of Chinese medicine	Western medicine treatment

							and western medicine	
8	NCT04244591	N/A	2020-1-26	2020-4-25	91	80	Methylprednisolone 40 mg q12h for 5 d	Standard care
9	NCT04251871	N/A	2020-1-22	2021-1-22	367	150	Conventional medicines and Traditional Chinese Medicines (TCMs) granules	Conventional medicines
10	ChiCTR2000029436	0	2020-02-01	2020-12-31	335	100	TCM syndrome differentiation treatment+ Western medicine treatment	Western medicine treatment
11	ChiCTR2000029432	0	2020-02-01	2020-04-30	90	72	Tanreqing injection	No
12	ChiCTR2000029431	0	2020-01-29	2021-12-31	338	45	Group A: Ankylosaurus Group B: Ankylosaurus+M1 suppression therapy Group C: Critical Treatment in Critical Period	
13	ChiCTR2000029381	4	2020-01-01	2020-12-31	366	400	XuebijingInjiection	Conventional treatment
14	ChiCTR2000029487	N/A	2020-02-10	2020-03-31	51	200	Isolation and oral GubiaoJiedu Ling Chinese medicine	Isolated observation
15	ChiCTR2000029479	N/A	2020-01-30	2020-05-01	93	10,000	Jinhao Artemisia Antipyretic Granules	non-intervention

							Huoxiangzhengqi	
16	ChiCTR 2000029468	N/A	2020-02-01	2020-06-30	151	120	Lopinavir/litonavir (LPV/r)+emtritabine (FTC)/Tenofovir alafenamide Fumarate tablets (TAF) in combination	Lopinavir / ritonavir
17	ChiCTR 2000029461	0	2020-02-03	2021-12-31	698	100	TCM decoctions+ basic conventional therapy	Basic conventional therapies
18	ChiCTR 2000029460	0	2020-02-03	2021-12-31	698	100	Shadowboxing +conventional treatment	Conventional treatments
19	ChiCTR 2000029459	0	2020-02-03	2021-12-31	698	100	Pulmonary rehabilitation+ Conventional treatment	Conventional treatment
20	ChiCTR 2000029439	0	2020-02-01	2021-12-31	700	120	TCM standard decoctions + basic western medical therapies	Basic western medical therapies
21	ChiCTR 2000029438	4	2020-02-01	2021-12-01	670	100	Conventional medicine + TCM	Western medical therapies
22	NCT04252274	3	2020-1-31	2020-12-31	336	30	Darunavir, Cobicistat + conventional treatments	Darunavir and Cobicistat
23	NCT04261517	3	2020-2-6	2020-12-31	330	30	Hydroxychloroquine and	Conventional treatments

							conventional treatments	
24	ChiCTR 2000029544	0	2020-02-04	2020-05-31	118	20	Current antiviral treatment+ BaloxavirMarboxil tablets	Current antiviral treatment
25	ChiCTR 2000029542	4	2020-02-03	2020-07-30	179	20	Chloroquine	Conventional management
26	ChiCTR 2000029541	N/A	2020-02-01	2020-12-01	305	80	DRV/c + Conventional treatment containing thymosin	LPV/r + Conventional treatment containing thymosin
27	ChiCTR 2000029539	0	2020-02-03	2021-02-02	366	328	Conventional standardized treatment and Lopinavir-Ritonavir	Conventional standardized treatment
28	ChiCTR 2000029518	0	2020-02-04	2020-04-30	87	80	Ordinary Chinese and Western Medicine	Ordinary Western medicine
29	ChiCTR 2000029517	0	2020-02-04	2020-04-30	87	100	Chinese medicine decoction	Placebo
30	ChiCTR 2000029496	4	2020-01-29	2021-01-29	367	60	Routine medical treatment+ Novaferon Atomization inhalation	On the basis of routine medical treatment, the patients were given lopinavir/ ritonavir tablets (Kaletra)
31	ChiCTR 2000029495	0	2020-02-03	2021-12-31	698	60	Traditional Chinese Medicine+ psychological intervention	Traditional Chinese Medicine

32	ChiCTR 2000029493	0	2020-02-03	2021-12-31	698	100	TCM decoctions+ basic western medical therapies	Basic western medical therapies
33	ChiCTR 2000029580	0	2020-01-31	2020-12-31	335	70	Ruxolitinib combined with mesenchymal stem cell	Routine treatment
34	ChiCTR 2000029589	0	2020-02-05	2021-12-31	330	60	Reduning injection combined with basic western medical therapies	Basic western medical therapies
35	ChiCTR 2000029600	0	2020-01-30	2020-04-29	91	60	Lopinavir and Ritonavir + alpha-Interferon atomization	Alpha-Interferon atomization
36	ChiCTR 2000029601	0	2020-02-01	2020-08-01	183	400	Health education+ Basic treatment of Western medicine+ Dialectical treatment of traditional Chinese medicine	Health education+ Basic treatment of western medicine
37	ChiCTR 2000029602	0	2020-02-01	2020-08-01	183	600	Health education, follow-up condition management by team of family doctors + Chinese	Health education, follow-up condition management by team of family doctors

							medicine treatment	
38	ChiCTR 2000029603	0	2020-02-06	2020-05-31	116	160	Conventional standardized treatment and ASC09/Ritonavir	Conventional standardized treatment + Lopinavir/Ritonavir
39	ChiCTR 2000029605	4	2020-02-05	2021-02-05	367	200	Low dose , Medium dose and High dose of Shuanghuanglian	Routine treatment
40	ChiCTR 2000029578	0	2020-02-06	2020-04-30	85	10,000	Integrated Traditional Chinese and Western Medicine	No
41	ChiCTR 2000029573	4	2020-02-05	2020-06-30	147	200	Novaferon injection + atomized inhalation + Arbidol Tablets	Arbidol Tablets
42	ChiCTR 2000029572	0	2020-02-05	2021-04-30	86	30	Conventional treatment combined with umbilical cord blood mononuclear cells group	Conventional treatment
43	ChiCTR 2000029569	0	2020-02-05	2021-04-30	86	30	Conventional treatment combined with umbilical cord mesenchymal stem cell conditioned	Conventional treatment

							medium group	
44	ChiCTR 2000029559	4	2020-01-31	2020-02-29	30	200	Group 1: Hydroxychloroquine 0.1 oral 2/d Group 2: Hydroxychloroquine 0.2 oral 2/d	Starch pill oral 2/ day
45	ChiCTR 2000029558	0	2020-01-29	2020-05-01	94	200	Chinese medicine treatment combined with Western medicine treatment	No
46	ChiCTR 2000029550	N/A	2020-01-29	2020-05-01	94	300	Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, tid, with warm water	Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water
47	ChiCTR 2000029549	N/A	2020-02-03	2020-05-01	89	200	Western medicine routine treatment combined with traditional Chinese medicine treatment	Western medicine routine treatment
48	ChiCTR 2000029548	0	2020-02-04	2020-06-03	121	30	Group A: BaloxavirMarboxil Group B: Favipiravir Group C: Lopinavir-Ritonavir	
49	NCT04260594	4	2020-02-07	2020-12-30	326	380	Arbidol tablets + basic treatment	Basic treatment

50	NCT042 61907	N/A	2020-02 -07	2020-06 -30	145	160	ASC09/riton avir + conventiona l standardize d treatment	Lopinavir/ritona vir tablet+ conventional standardized treatment
51	NCT042 57656	3	2020-02 -06	2020-04 -03	58	453	active remdesivir	Placebos matched remdesivir
52	ChiCTR 200002 9636	0	2020-02 -07	2020-07 -30	175	40	Conventiona l standardize d treatment+ vMIP atomized inhalation	No
53	ChiCTR 200002 9626	0	2020-02 -17	2020-08 -01	167	20	N/A	N/A
54	ChiCTR 200002 9621	4	2020-01 -01	2020-12 -31	365	380	Arbidol tablets + basic treatment	Basic treatment
55	ChiCTR 200002 9609	4	2020-02 -10	2020-12 -31	324	177	Group 1: mild-moderate chloroquine Group 2: mild-moderate Lopinavir/ritonavir Group 3: mild-moderate combination Group 4: severe-chloroquine Group 5: severe- Lopinavir/ritonavir	
56	ChiCTR 200002 9606	0	2020-01 -15	2022-12 -31	880	63	Group A: Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations Group A control: Conventional treatment Group B1: Artificial liver therapy+ conventional treatment	

							Group B2: Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+ conventional treatment Group B control: Conventional treatment	
57	ChiCTR 2000029625	0	2020-02-17	2020-08-01	167	80	inapplicable	inapplicable
58	NCT04263402	4	2020-02-01	2020-07-01	152	100	Basic symptomatic supportive treatment +methylprednisolone (<40mg/d intravenous drip for 7)	Basic symptomatic supportive treatment +methylprednisolone (40-80 mg/d intravenous drip for 7 d)
59	NCT04254874	4	2020-02-01	2020-07-01	152	100	Abidol Hydrochloride combined with interferon atomization	Abidol hydrochloride
60	NCT04261270	N/A	2020-02-01	2020-07-01	152	180	Group 1: ASC09F + Oseltamivir Group 2: Ritonavir+ Oseltamivir Group 3: Oseltamivir	
61	NCT04252664	3	2020-02-01	2020-04-07	75	308	Remdesivir	Remdesivir placebo
62	NCT04261426	2,3	2020-2-10	2020-06-30	142	80	IVIG therapy+ standard care	Standard care
63	NCT04255017	4	2020-02-01	2020-07-01	152	400	Group 1: Abidol hydrochloride Group 2: Oseltamivir	Symptomatic supportive treatment

							Group 3: Lopinavir/ritonavir	

Table 4 Summary of observational registered clinical trials.

No	Register number	Study phrase	Start time	End time	Time consuming (days)	Sample	Intervention	Control
1	ChiCTR2000029637	0	2020-02-07	2020-04-10	63	100	Xinguan No.1 prescription + routine treatment	Routine treatment
2	ChiCTR2000029430	N/A	2020-02-02	2020-12-01	303	600	Nil	N/A
3	ChiCTR2000029462	N/A	2020-02-01	2020-12-31	334	200	N/A	N/A
4	ChiCTR2000029437	N/A	2020-02-01	2020-12-31	334	300	Treat according to the guidelines	N/A
5	ChiCTR2000029592	4	2020-02-05	2020-08-31	208	1,000	History of use of Abidor	No history of using Abidor
6	ChiCTR2000029624	N/A	2020-02-08	2021-02-07	365	500	Traditional Chinese medicine	N/A
7	NCT04262921	N/A	2020-02-07	2021-08-07	547	500	N/A	N/A
8	NCT04256395	N/A	2020-02-01	2021-07-31	546	300,000	mobile internet survey on self-test	N/A
9	NCT04245631	N/A	2020-01-01	2021-12-30	729	50	Recombinase aided	N/A

10	NCT04255940	N/A	2020-01-30	2021-04-30	456	12,000	amplification (RAA) assay	
							N/A	N/A
11	NCT04259892	N/A	2020-02-04	2021-02-04	366	300	Biological: 2019-nCoV PCR (Nasopharyngeal swabs)	N/A
12	ChiCTR2000029579	0	2020-01-31	2020-12-31	335	200	Nil	Routine treatment

Table 3 The methodology quality of the observational trials using Newcastle-Ottawa scale.

Register number	Representativeness of the exposed cohort	Selection of the non exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	Scores
ChiCTR2000029637	1	1	1	1	1	0	1	0	6
ChiCTR2000029430	1	1	1	1	1	0	0	0	5
ChiCTR2000029462	1	1	1	1	1	1	0	0	6
ChiCTR2000029437	1	1	1	1	1	1	0	0	6
ChiCTR2000029592	1	1	1	1	1	1	0	0	6
ChiCTR2000029624	1	1	1	1	1	1	0	0	6
NCT04262921	1	1	1	1	1	0	1	0	6
NCT04256395	1	1	1	1	1	0	1	0	6
NCT04245631	1	1	1	1	0	0	1	0	5
NCT04255940	1	1	1	1	0	0	0	0	4
NCT04259892	1	1	1	1	1	0	1	0	6
ChiCTR2000029579	1	1	1	1	1	0	0	0	5

Note: A study can be awarded a maximum of one point for each numbered item within the Selection and Outcome categories. A maximum of two points can be given for Comparability.

Figure 1 The flowchart of retrieval of the registered clinical trials.

Figure 2 The primary sponsors of the registered clinical trials.

Figure 3 Risk of bias graph across all included interventional clinical trials.

Figure 4 Risk of bias graph across all included observational studies.